颈项透明层增厚胎儿的微阵列与RASopathy疾病检测
该回顾性研究纳入226例颈项透明层厚度≥3.5 mm的妊娠,QF-PCR检出51.3%染色体非整倍体,剩余110例中核型/CMA检出8.2%异常,RASopathy检测检出2.9%致病性变异,RASopathy筛查最佳NT截断值为7.9 mm。作者认为CMA和RASopathy分子检测是重要检查,遗传检测联合胎儿超声可影响妊娠结局并提供再发风险。
要点
- NT≥3.5 mm时QF-PCR可检出51.3%染色体非整倍体,应作为一线检测。
- QF-PCR阴性者核型/CMA可额外检出8.2%异常及5例意义不明变异。
- RASopathy检测在103例中检出3例致病性变异(2.9%),本人群最佳NT截断值为7.9 mm。
核心结论
- CMA和RASopathy分子检测是NT≥3.5 mm妊娠的重要检查,遗传检测联合胎儿超声可影响妊娠结局并提供再发风险。
研究设计与样本
- 回顾性病历审查,纳入2013年1月至2015年12月转诊至西奈山医院产前诊断与医学遗传学项目的NT≥3.5 mm且行绒毛膜取样或羊膜腔穿刺的患者,共226例,QF-PCR为首线非整倍体检测,阴性者行核型分析和/或CMA,正常者行9个已知基因的RASopathy致病性变异检测,并由专家操作行详细胎儿超声和超声心动图检查。
关键影像表现/征象
- QF-PCR在116/226(51.3%)患者中检出染色体非整倍体。
- 核型/CMA在9/110(8.2%)患者中检出异常/致病性细胞遗传学结果,并检出5例意义不明变异。
- RASopathy检测在103例中检出3例致病性变异,检出率2.9%,并检出1例意义不明变异。
- 92/110(83.6%)患者遗传学检查正常,其中孕14-16周详细胎儿超声检出24例(26.1%)结构异常,孕18-22周详细超声检出15例(16.3%)异常,胎儿超声心动图检出9例(9.8%)心脏异常。
诊断标准与关键数值
- 本人群中RASopathy筛查的最佳NT截断值为7.9 mm。
- RASopathy检测覆盖9个已知基因。
- QF-PCR作为非整倍体一线检测,阴性后行核型分析和/或CMA,正常后行RASopathy检测。
临床应用与阅片要点
- 作者认为CMA和RASopathy分子检测是NT≥3.5 mm妊娠的重要检查。
- 作者认为遗传检测联合胎儿超声检查可提供影响妊娠结局和再发风险的有价值信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the incidence of chromosomal abnormalities, submicroscopic chromosomal abnormalities and RASopathy-disorder (RD) pathogenic variants in a cohort of pregnancies with nuchal translucency thickness (NT) ≥ 3.5 mm, and to propose a clinical protocol for surveillance of this group of patients.
METHODS: This was a retrospective chart review of patients referred to The Prenatal Diagnosis and Medical Genetics Program at Mount Sinai Hospital between January 2013 and December 2015, due to NT ≥ 3.5 mm, who underwent chorionic villus sampling or amniocentesis. Patients underwent extensive genetic counseling prior to invasive procedures and testing. Quantitative fluorescence polymerase chain reaction (QF-PCR) was performed as the first-line test for aneuploidy. If the result was negative, patients underwent karyotyping and/or chromosomal microarray analysis (CMA), and if the findings were normal, they had testing for RD pathogenic variants, which included nine known genes. Patients also underwent detailed fetal ultrasound examinations and echocardiography, performed by expert operators.
RESULTS: A total of 226 eligible patients were identified. In 116/226 (51.3%) patients, QF-PCR identified a chromosomal aneuploidy. The remaining 110/226 (48.7%) patients had further genetic testing. Karyotyping/CMA detected an abnormal/pathogenic cytogenetic result in 9/110 (8.2%) patients, as well as five variants of unknown significance (VOUS). RD testing yielded three pathogenic variants (3/103), giving a detection rate of 2.9%, and one VOUS. The optimal NT cut-off for RD screening was 7.9 mm in this population. In 92/110 (83.6%) patients, the genetic investigations were normal. Of these pregnancies, an early (14-16 weeks' gestation) detailed fetal ultrasound examination identified a structural abnormality in 24 (26.1%), 15 (16.3%) had an abnormal detailed ultrasound examination at 18-22 weeks' gestation and fetal echocardiography showed a cardiac abnormality in nine (9.8%). The birth outcome in the 83 pregnancies that had normal genetic investigations and known outcome included seven (8.4%) cases of termination of pregnancy, seven (8.4%) cases of intrauterine fetal death and 69 (83.1%) cases of live birth. Nine (9.8%) patients were lost to follow-up.
CONCLUSIONS: Both CMA and molecular testing for RD are important investigations in pregnancies with NT ≥ 3.5 mm. The use of genetic testing combined with fetal ultrasound examination provides valuable information that can influence pregnancy outcome, and provide recurrence risks, in this patient population. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Sinajon P, Chitayat D, Roifman M, et al. Microarray and RASopathy-disorder testing in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol. 2020. PMID: 31115076. doi:10.1002/uog.20352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。